ClinicalTrials.gg

Program

TLR7 Agonist JNJ-64794964

Also written as “TQ-A3334 tablets”, “TQ-A3334” and “TQA3334 Tablet”.

In Sino Biopharmaceutical’s pipeline, TLR-7激动剂. Its studies are mostly in Hepatitis B, Chronic · Hepatitis B · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 2, since Nov 26, 20196 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical51 open or runningphase 2since Nov 26, 2019Nov 26, 2019none ahead
Johnson & Johnson10 open or runningphase 1since Aug 15, 2017Aug 15, 2017none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQ-A3334, phase 2, as of Nov 16, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 15, 2017First study: phase 1 study in Hepatitis BNew to Johnson & JohnsonJohnson & Johnson · NCT03285620 · 42 enrolled · New Zealand
  2. Nov 26, 2019Sino Biopharmaceutical’s first study: phase 2 study in Hepatitis B, ChronicNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT04180150 · 12 enrolled · China
  3. Feb 16, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungSino Biopharmaceutical · NCT04273815 · 40 enrolled · China
  4. Nov 30, 2023Phase 1 study in Hepatitis BSino Biopharmaceutical · NCT06160895 · 40 enrolled · China
  5. Jul 11, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungSino Biopharmaceutical · NCT06507891 · 30 enrolled · China
  6. Nov 20, 2024Phase 2 study in Hepatitis B, ChronicSino Biopharmaceutical · NCT06706310 · 116 enrolled · China

TargetBeta

“TLR-7激动剂”the company's pipeline, read by Claude · source

Other programs on TLR7

ProgramCompanyFurthest phaseStudies
resiquimodruleStaidson (Beijing) Biopharmaceuticalsphase 314
enpatoranruleMerck KGaA, Darmstadt, Germanyphase 312
afimetoranruleBristol-Myers Squibbphase 312
Cholesteryl Pullulan Nanoparticle-formulated TLR7/8 Agonist UI-102ruleunited-immunity-co-ltdphase 21
PRTX007ruleprimmune-therapeutics-incphase 21

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06706310Hepatitis B, Chronic · China2Active, not recruitingSino BiopharmaceuticalDec 7, 2025116
NCT06507891Carcinoma, Non-Small-Cell Lung · China2TerminatedSino BiopharmaceuticalAug 25, 202330
NCT06160895Hepatitis B · China1CompletedSino BiopharmaceuticalJun 24, 202440
NCT04273815Carcinoma, Non-Small-Cell Lung · China2UNKNOWNSino BiopharmaceuticalJan 31, 202140
NCT04180150Hepatitis B, Chronic · China2UNKNOWNSino BiopharmaceuticalSep 30, 202012
NCT03285620Hepatitis B · New Zealand1CompletedJohnson & JohnsonNov 14, 201842

How it is read

Names in the registry

  • “TQ-A3334 tablets”, 2 entries
  • “TQ-A3334”, 2 entries
  • “TQA3334 Tablet”, 1 entry
  • “AL-034”, 1 entry
  • “TQ-A3334 tablets + Anlotinib capsules”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.